Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: Effects of heterogeneity of disease course in placebo cohorts

Journal of Neurology Neurosurgery and Psychiatry

Volumn 68, Issue 4, 2000, Pages 450-457

  Liu, Clarence ^a   Blumhardt, Lance D ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Disability outcome measures; Multiple sclerosis; Treatment trials

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; STATISTICAL ANALYSIS;

EID: 0034101317     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.68.4.450     Document Type: Article

References (39)

1. The IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
2. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-76.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
4. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997;349:589-93.
5. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
6. Whitaker JN, McFarland HF, Rudge P, et al. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995;1:37-47.
7. Hughes RAC, Sharrack B. More immunotherapy for multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:239-41.
8. Liu C, Blumhardt LD. Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: can we do better? Multiple Sclerosis 1999;5:22-8.
9. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 1989;112:133-46.
10. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with 25 years of follow-up. Brain 1993;116:117-34.
11. Noseworthy JH. Are placebo-controlled clinical trials still ethical in multiple sclerosis? In: Thompson AJ, Polman C, Hohlfeld R, eds. Multiple sclerosis: clinical challenges and controversies. London: Martin Dunitz, 1997:177-93.
12. Rice G, Ebers G. Interferons in the treatment of multiple sclerosis. Do they prevent the progression of the disease? Arch Neurol 1998;55:1578-80.
13. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
14. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon β-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997;49:358-63.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
16. Liu C, Li Wan Po A, Blumhardt LD. Summary measure statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:726-9.
17. Weinshenker BG, Rice GPA, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991;114:1057-67.
18. Ellison GW, Myers LW, Leake BD, et al. Design strategies in multiple sclerosis clinical trials. Ann Neurol 1994;36:S108-12.
19. Wingerchuk DM, Noseworthy JH, Weinshenker BG. Clinical outcome measures and rating scales in multiple sclerosis trials. Mayo Clin Proc 1997;72:1070-9.
20. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419-28.
21. Liu C, Blumhardt LD, Li Wan Po A. Reply to correspondence by Simonian NA, McAllister A, Hull J. Summary measure statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1999;66:553-4.
22. Weinshenker BG, Issa M, Baskerville J. Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology 1996:46:1613-19.
23. Goodkin DE. Interferon β therapy for multiple sclerosis. Lancet 1998;352:1486-7.
24. McAlpine D, Compston N. Some aspects of the natural history of disseminated sclerosis. Q J Med 1952;82:135-67.
25. Weinshenker BG, Issa M, Baskerville J. Long-term and short-term outcome of multiple sclerosis. A 3 year follow up study. Arch Neurol 1996;53:353-8.
26. Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type with a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol 1989;46:1107-12.
27. Rudick RA, Antel J, Confavreux C, et al. Recommendations from the clinical outcome assessment task force of the National Multiple Sclerosis Society. Ann Neurol 1997;42: 379-82.
28. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-82.
29. Sharrack B, Hughes RAC. The Guy's neurological disability scale (GNDS): a new disability measure for multiple sclerosis. Multiple Sclerosis 1999;5:223-33.
30. Rudick RA, Antel J, Confavreux C, et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996;40:469-79.
31. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-7.
32. Ferguson B, Matyszak MK, Esiri MM, et al. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-9.
33. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278-85.
34. Fu L, Matthews PM, De Stefano N, et al. Imaging axonal change of normal-appearing white matter in multiple sclerosis. Brain 1998;121:103-13.
35. Liu C, Edwards S, Gong Q, et al. Three dimensional MRI estimates of brain and spinal cord atrophy. J Neurol Neurosurg Psychiatry 1999;66:323-30.
36. Müller R. Studies on disseminated sclerosis: with special reference to symptomatology, course and progress. Acta Med Scand 1949;133(suppl 222):1-214.
37. Alexander L, Berkeley AW, Alexander AM. Prognosis and treatment of multiple sclerosis: quantitative nosometric study. JAMA 1958;166:1943-9.
38. Morrisey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5 year follow up study. Brain 1993;116:135-46.
39. Sharrack B, Hughes RAC, Soudain S, et al. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain 1999;122:141-59.